SG11202005990RA - Process for providing pegylated protein composition - Google Patents

Process for providing pegylated protein composition

Info

Publication number
SG11202005990RA
SG11202005990RA SG11202005990RA SG11202005990RA SG11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA SG 11202005990R A SG11202005990R A SG 11202005990RA
Authority
SG
Singapore
Prior art keywords
protein composition
pegylated protein
providing
providing pegylated
composition
Prior art date
Application number
SG11202005990RA
Other languages
English (en)
Inventor
Wolfgang Koehnlein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11202005990RA publication Critical patent/SG11202005990RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1816Erythropoietin [EPO]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/20Partition-, reverse-phase or hydrophobic interaction chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/505Erythropoietin [EPO]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202005990RA 2017-12-29 2018-12-28 Process for providing pegylated protein composition SG11202005990RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17211124 2017-12-29
PCT/EP2018/097122 WO2019129876A1 (en) 2017-12-29 2018-12-28 Process for providing pegylated protein composition

Publications (1)

Publication Number Publication Date
SG11202005990RA true SG11202005990RA (en) 2020-07-29

Family

ID=60954809

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005990RA SG11202005990RA (en) 2017-12-29 2018-12-28 Process for providing pegylated protein composition

Country Status (7)

Country Link
US (1) US20200323993A1 (ja)
EP (1) EP3731871B1 (ja)
JP (2) JP7137625B2 (ja)
KR (1) KR102523239B1 (ja)
CN (1) CN111741770A (ja)
SG (1) SG11202005990RA (ja)
WO (1) WO2019129876A1 (ja)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1991006666A1 (en) 1989-11-06 1991-05-16 Cell Genesys, Inc. Production of proteins using homologous recombination
AU645294B2 (en) 1989-12-22 1994-01-13 Merck Serono Sa Endogenous gene expression modification with regulatory element
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
JPH07509128A (ja) 1992-07-13 1995-10-12 バイオネブラスカ・インコーポレーテッド 組換型ポリペプチドの修飾方法
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
HU228488B1 (en) 1999-01-29 2013-03-28 Amgen Inc Gcsf conjugates
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
CA2450950A1 (en) * 2001-06-22 2003-01-03 Pharmacia Corporation Chemically-modified progenipoietin conjugates
CA2507904C (en) 2002-12-19 2014-12-02 M. Elizabeth Snell Cyanovirin variant-polymer conjugates
AP2007003919A0 (en) 2004-08-31 2007-02-28 Pharmacia & Upjohn Co Llc Glycerol branched polyethylene glycol human growthhormone conjugates, process for their prepation a nd methods of use thereof
WO2007010552A2 (en) * 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
AR067537A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
EP2350118B1 (en) * 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
US8697844B2 (en) 2009-11-24 2014-04-15 Novo Nordisk A/S Method of purifying pegylated proteins
MX342444B (es) * 2010-09-14 2016-09-29 F Hoffmann-La Roche Ag * Metodo para purificar eritropoyetina conjugada con polietilenglicol (peg).
WO2013138694A1 (en) * 2012-03-16 2013-09-19 Enzon Pharmaceuticals, Inc. Polymeric conjugates of c-1 inhibitors

Also Published As

Publication number Publication date
KR20200104380A (ko) 2020-09-03
JP7137625B2 (ja) 2022-09-14
EP3731871B1 (en) 2023-10-04
EP3731871A1 (en) 2020-11-04
US20200323993A1 (en) 2020-10-15
JP2022169794A (ja) 2022-11-09
KR102523239B1 (ko) 2023-04-18
JP2021508715A (ja) 2021-03-11
WO2019129876A1 (en) 2019-07-04
CN111741770A (zh) 2020-10-02
EP3731871C0 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
HK1249527A1 (zh) Cd137特異性的蛋白
DK3445788T3 (en) Novel bispecific polypeptides against cd137
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
GB201503133D0 (en) Chimeric protein
IL288613A (en) Multispecific proteins
SG11201704010UA (en) Fibroin-derived protein composition
ZA201708041B (en) Novel proteins specific for lag-3
DK3737402T3 (en) Modificeret protein
GB201515745D0 (en) Proteins
GB201511787D0 (en) Proteins
IL258570A (en) Stable protein preparations
EP3463414C0 (en) PROTEIN INTERFACES
GB201608197D0 (en) Novel proteins
EP3377633C0 (en) PRODUCTION OF RECOMBINANT PROTEINS
HK1257745A1 (zh) 肽組合物
GB201506223D0 (en) Chimeric protein
SG11202006140TA (en) Process for providing pegylated protein composition
ZA202003722B (en) Modified globin proteins
ZA201901862B (en) Modified factor h binding protein
GB201513033D0 (en) Proteins
GB2558968B (en) G Proteins
SG11202005952TA (en) Process for providing pegylated protein composition
SG11202005990RA (en) Process for providing pegylated protein composition
EP3505624A4 (en) COMPOSITION FOR ANTI-RNA VIRUS WITH EPRS PROTEIN OR FRAGMENT THEREOF